Loading Please wait, logging in.
Join ALFA Member Login RSS Feed
Tagline Image
Bookmark and Share  

Antipsychotics Beneficial For Some Individuals With Alzheimer’s

A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.

Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.

Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City.  “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."

For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study  Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.

 
Suggested Articles:

7/28/2016
Facts and Figures, Health Care, Memory Care Best Practices and Research, Memory Care Education, News, Research
A slew of new research was discussed at the Alzheimer’s Association International Conference in Toronto this week. Two studies suggested that a low-c...
7/21/2016
The Centers for Medicare & Medicaid Services has proposed changes to the way it pays for primary care with a focus on care management and behavioral a...
7/21/2016
Clinical Quality and Quality Care Delivery, Facts and Figures, Memory Care Best Practices and Research, Memory Care Education, News, Reports, Research
A gene variant whose carriers are more likely to develop Alzheimer’s disease than other people may show its effects on the brain and thinking in child...
7/13/2016
C-TAC is hosting the National Summit on Advanced Illness Care – the premier event for visionaries in advanced illness care who are actively reshaping ...
7/7/2016
Advocacy, Community Awareness and Education, Core Principles, Engage, Facts and Figures, Memory Care Best Practices and Research, News, Research, Resident and Family Services
The latest draft bill from the House Appropriations Committee for funding programs in fiscal 2017 includes $73.2 billion for the Health and Human Serv...
6/29/2016
Engage, Facts and Figures, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education, News, Research
Eli Lilly has worked for nearly 30 years on drugs for Alzheimer’s disease by focusing on a protein called tau but is changing its tactics in hopes for...
6/2/2016
Facts and Figures, Falls Prevention, Health and Wellness, Managed Risk, Research
Seventy-year-old women are at a greater risk of falling compared to men, according to new research published in the Journal of Post-Acute and Long-Ter...
5/19/2016
CEO, cheatsheet, Clinical Quality and Quality Care Delivery, End of Life, Facts and Figures, Health and Wellness, Health Care, Medicare, Research, Wellness Program
The new Medicare system for reimbursing providers outlined in the Medicare Access and CHIP Reauthorization Act, or MACRA, may not adequately reward go...
5/12/2016
Argentum’s Memory Care Executive Peer Group with the support of MatrixCare has commissioned a new project to recognize innovations improving resident ...
5/10/2016
Advocacy, Choice, Clinical Quality and Quality Care Delivery, Core Principles, Dignity, Independence, Quality of Life, Regulations, Regulatory Compliance
Argentum launched the first phase of professional standards for operators of senior living communities this year and is looking to identify more compr...
   
10/23/2012


Additional Resources